

**Table S1** Univariate and multivariate analyses of clinical parameters for PFS of chemo-antiangiogenesis combinations after TKI resistance (n=100)

Factors	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Age ( $\leq 58 / > 58$ years)	1.668	1.058–2.628	0.0215	1.428	0.841–2.426	0.187
Gender (male/female)	0.6625	0.4216–1.041	0.0589	1.609	0.921–2.811	0.095
Smoking status (current or former/never)	0.9485	0.5630–1.598	0.8431			
EGFR subtypes (19Del/L858R)	0.8754	0.5227–1.466	0.6011			
Median PFS of TKIs <sup>a</sup> ( $\leq 3.1 / > 3.1$ months)	2.178	1.008–4.706	0.0057	2.040	0.947–4.395	0.069
T790M status after TKIs resistance (positive/negative)	1.459	0.7369–2.890	0.2022			
PD-L1 status ( $\geq 1\% / < 1\%$ )	0.6667	0.0902–4.928	0.6419			
Metastasis sites ( $\leq 1 / > 2$ )	0.9701	0.6182–1.522	0.8910			
Lines of therapy ( $2 / \geq 3$ )	0.7471	0.4683–1.192	0.1870			
Lymphocyte count <sup>a</sup> ( $\leq 2.00 / > 2.00 \times 10^9 / L$ )	2.135	1.138–4.008	0.0495	1.944	0.647–5.846	0.237
Neutrophil count <sup>a</sup> ( $\leq 6.99 / > 6.99 \times 10^9 / L$ )	0.4176	0.1442–1.210	0.0144	1.193	0.418–3.406	0.742
Monocyte count <sup>a</sup> ( $\leq 0.68 / > 0.68 \times 10^9 / L$ )	0.5632	0.2617–1.212	0.0602	0.738	0.344–1.583	0.345
Eosinophil count <sup>a</sup> ( $\leq 0.09 / > 0.09 \times 10^9 / L$ )	1.610	0.9405–2.755	0.0479	1.280	0.731–2.243	0.388
Basophil count <sup>a</sup> ( $\leq 0.03 / > 0.03 \times 10^9 / L$ )	1.255	0.7323–2.152	0.4217			
Platelet count <sup>a</sup> ( $\leq 373 / > 373 \times 10^9 / L$ )	0.5752	0.2689–1.230	0.0698	0.334	0.119–0.937	0.037
NLR <sup>a</sup> ( $\leq 1.82 / > 1.82$ )	0.5319	0.2625–1.078	0.1611			
MLR <sup>a</sup> ( $\leq 0.26 / > 0.26$ )	1.215	0.7322–2.016	0.4224			
PLR <sup>a</sup> ( $\leq 124.35 / > 124.35$ )	0.5449	0.3309–0.8975	0.0272	0.941	0.453–1.955	0.871

<sup>a</sup>, the assessment of the optimal cutoff values were conducted by X-tile software. Abbreviations: EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

**Table S2** Univariate and multivariate analyses of clinical parameters for PFS of chemo-immunotherapy combinations after TKI resistance (n=44)

Factors	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
Age ( $\leq 63 / > 63$ years)	1.134	0.5077–2.534	0.7550			
Gender (male/female)	0.9730	0.4441–2.132	0.9442			
Smoking status (current or former/never)	0.7240	0.2475–2.118	0.5908			
EGFR subtypes (19Del/L858R)	1.113	0.4857–2.549	0.7976			
Median PFS of TKIs <sup>a</sup> ( $\leq 7.1 / > 7.1$ months)	1.504	0.6431–3.519	0.2833			
T790M status after TKIs resistance (positive/negative)	3.028	0.5750–15.94	0.0275	3.527	0.690–18.026	0.130
PD-L1 status ( $\geq 1\% / < 1\%$ )	0.5465	0.0567–5.266	0.6076			
Metastasis sites ( $\leq 1 / > 2$ )	0.6718	0.2684–1.682	0.3360			
Lines of therapy ( $2 / \geq 3$ )	0.5618	0.2329–1.355	0.1258			
Lymphocyte count <sup>a</sup> ( $\leq 1.06 / > 1.06 \times 10^9 / L$ )	3.401	0.9345–12.38	0.0020	1.588	0.292–8.651	0.593
Neutrophil count <sup>a</sup> ( $\leq 6.06 / > 6.06 \times 10^9 / L$ )	0.4695	0.1696–1.300	0.0657	0.950	0.238–3.793	0.943
Monocyte count <sup>a</sup> ( $\leq 0.40 / > 0.40 \times 10^9 / L$ )	0.4886	0.2134–1.119	0.1324			
Eosinophil count <sup>a</sup> ( $\leq 0.15 / > 0.15 \times 10^9 / L$ )	1.890	0.8496–4.203	0.0769	1.577	0.505–4.925	0.433
Basophil count <sup>a</sup> ( $\leq 0.01 / > 0.01 \times 10^9 / L$ )	1.458	0.6599–3.221	0.3266			
Platelet count <sup>a</sup> ( $\leq 264 / > 264 \times 10^9 / L$ )	0.3876	0.1213–1.239	0.0229	0.256	0.076–0.865	0.028
NLR <sup>a</sup> ( $\leq 4.00 / > 4.00$ )	0.4046	0.1552–1.055	0.0185	0.886	0.212–3.693	0.868
MLR <sup>a</sup> ( $\leq 0.42 / > 0.42$ )	0.4471	0.1681–1.189	0.0409	0.554	0.167–1.839	0.335
PLR <sup>a</sup> ( $\leq 194.17 / > 194.17$ )	0.3184	0.0817–1.241	0.0069	1.501	0.268–8.426	0.644

<sup>a</sup>, the assessment of the optimal cutoff values were conducted by X-tile software. Abbreviations: EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; PD-L1, programmed cell death ligand 1; PFS, progression-free survival; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.